中期因子在胰腺癌组织中的表达及其临床意义

The expression of midkine(MK) in pancreatic carcinoma and its clinical significance

目的探讨中期因子 (midkine,MK)的蛋白表达水平与胰腺癌血管生成、生物学特性和预后的关系。方法采用免疫组织化学方法检测 5 2例胰腺癌组织中MK的蛋白表达和微血管密度(MVD) ,并与临床病理及预后指标作对照分析。结果胰腺癌的MVD平均为 6 4± 18,MK表达阳性率为 73%。有淋巴结转移、Ⅲ～Ⅳ期和MVD高的患者 ,MK阳性表达率明显高于无淋巴结转移、Ⅰ～Ⅱ期和MVD低的患者 (P <0 0 1)。MK高表达患者术后生存时间比MK低表达患者明显缩短 (P <0 0 1)。结论MK的蛋白表达水平能反映胰腺癌细胞的恶性程度 ,可作为胰腺癌转移和预后分析的指标。

ObjectiveTo investigate the expression of midkine(MK) and its relation with angiogenesis, biological features and prognosis of pancreatic carcinoma(PC).MethodsMK expression and microvessel density(MVD) were determined in 52 cases of human PC with immunohistochemistry and results were compared with pathology.ResultsMean MVD of PC was 64±18 and positive expression of MK was detected in 38 cases (73%). The positive rate of MK was significantly lower in cases of without metastasis and at early clinical stage (stageⅠ～Ⅱ) than that with metastasis and at stage Ⅲ～Ⅳ. MVD was significantly higher in MK-positive PC than in MK-negative PC (P<0.01). Follow-up showed that postoperative survival time was shorter in patients with positive expression of MK.ConclusionsMK is closely related to angiogenesis PC. MK expression is one of the predictors for the biological behavior of PC.